Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
9.38
+0.84 (9.84%)
May 5, 2026, 11:03 AM EDT - Market open
Emergent BioSolutions Revenue
Emergent BioSolutions had revenue of $156.10M in the quarter ending March 31, 2026, a decrease of -29.75%. This brings the company's revenue in the last twelve months to $676.80M, down -29.89% year-over-year. In the year 2025, Emergent BioSolutions had annual revenue of $742.90M, down -28.81%.
Revenue (ttm)
$676.80M
Revenue Growth
-29.89%
P/S Ratio
0.72
Revenue / Employee
$752,000
Employees
900
Market Cap
483.97M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 742.90M | -300.70M | -28.81% |
| Dec 31, 2024 | 1.04B | -5.70M | -0.54% |
| Dec 31, 2023 | 1.05B | -68.20M | -6.10% |
| Dec 31, 2022 | 1.12B | -656.10M | -36.99% |
| Dec 31, 2021 | 1.77B | 196.30M | 12.45% |
| Dec 31, 2020 | 1.58B | 471.30M | 42.61% |
| Dec 31, 2019 | 1.11B | 323.60M | 41.36% |
| Dec 31, 2018 | 782.40M | 221.50M | 39.49% |
| Dec 31, 2017 | 560.90M | 72.10M | 14.75% |
| Dec 31, 2016 | 488.80M | -531.00K | -0.11% |
| Dec 31, 2015 | 489.33M | 84.87M | 20.98% |
| Dec 31, 2014 | 404.47M | 91.72M | 29.33% |
| Dec 31, 2013 | 312.75M | 30.86M | 10.95% |
| Dec 31, 2012 | 281.89M | 8.50M | 3.11% |
| Dec 31, 2011 | 273.38M | -12.79M | -4.47% |
| Dec 31, 2010 | 286.17M | 51.39M | 21.89% |
| Dec 31, 2009 | 234.79M | 56.23M | 31.49% |
| Dec 31, 2008 | 178.55M | -4.36M | -2.38% |
| Dec 31, 2007 | 182.92M | 30.18M | 19.76% |
| Dec 31, 2006 | 152.73M | 22.04M | 16.87% |
| Dec 31, 2005 | 130.69M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tilray Brands | 858.28M |
| Organogenesis Holdings | 564.17M |
| Esperion Therapeutics | 403.14M |
| Evolus | 301.79M |
| Ironwood Pharmaceuticals | 296.15M |
| Akebia Therapeutics | 236.20M |
| Canopy Growth | 203.04M |
| Kamada | 180.46M |
EBS News
- 4 days ago - Emergent BioSolutions Earnings Call Transcript: Q1 2026 - Transcripts
- 4 days ago - Emergent BioSolutions Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 5 days ago - Emergent BioSolutions Receives Approval from Singapore Health Sciences Authority for Expanded Indication of ACAM2000® (Smallpox and Mpox (Vaccinia) Vaccine, Live) to Include Mpox - GlobeNewsWire
- 6 days ago - Emergent BioSolutions Transcript: AGM 2026 - Transcripts
- 6 days ago - Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - GlobeNewsWire
- 6 days ago - Emergent BioSolutions Partners with Professional Baseball Player Davis Schneider to Raise Awareness of NARCAN® Nasal Spray Among Canadians and Help Save Lives - GlobeNewsWire
- 7 days ago - Emergent BioSolutions and Substipharm Biologics Announce Strategic Manufacturing Partnership to Support Japanese Encephalitis Vaccine in the United States - GlobeNewsWire
- 18 days ago - Emergent BioSolutions to Report First Quarter 2026 Financial Results on April 30, 2026 - GlobeNewsWire